After Third Harmonic Bio (THRD) announced that the company has decided to discontinue the ongoing Phase 1b study of its investigational drug candidate THB001 after observing asymptomatic liver transaminitis in two trial subjects, Guggenheim analyst Yatin Suneja said the news "puts them even further behind" competitor Celldex (CLDX), which has treated more than 120 patients to date with barzolvolimab with no reported cases of transaminitis. Suneja, who continues to like barzo’s profile in chronic urticarias and sees Celldex as "the clear leader in the c-KIT space" with one less competitor, keeps a Buy rating on Celldex shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CLDX:
- Celldex to host conference call
- Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria
- Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
- Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
- Celldex to Participate in Upcoming November Investor Conferences